| Jean
M. George,
General Partner Jean George joined Advanced Technology Ventures as a Partner in 2002, with 20 years of experience in the biopharmaceutical industry, including 10 years at Genzyme Corporation. Jean assesses new deals in the life sciences and therapeutics markets, and utlizes her operational skills to actively assist portfolio companies on their strategic planning and development. Jean is currently on the Boards of NuGenesis Technologies Corp. and Microbia, Inc. Prior to joining ATV, Jean was a Director at BancBoston Ventures, where she led the health care team’s investment activity in NuGenesis Technologies Corp., Microbia, Inc., Syntonix Pharmaceuticals and Neurometrix, Inc. Previously, during Jean’s tenure at Genzyme, she held a variety of operational roles in marketing, product development and business development, including Vice President of Global Sales and Marketing. Jean was a member of the founding team of the Genzyme Tissue Repair Division, and held responsibilities for identifying new product opportunities and potential acquisition candidates for the Therapeutic Products Division. In addition to her extensive operating background, Jean spent six years working in chemistry and bioresearch fields. Jean earned an MBA from Simmons College Graduate School of Management and a BS in Biology from the University of Maine. |
 |
| William
C. Mills III, Partner Mr. Mills has over 21 years of venture capital experience, and focuses on investments in the biotechnology, emerging pharmaceutical and medical technology sectors. He is currently a Director of Ardais Corporation (Lead Director), Enanta Pharmaceuticals Inc. and Stereotaxis, Inc., and is a member of the Research and Technology Development Committee and Equity Subcommittee of Beth Israel Deaconess Medical Center (Harvard). Before joining Advent, Mr. Mills spent eleven years with The Venture Capital Fund of New England as a General Partner. His specific area of responsibility was the partnership's pharmaceutical, biotechnology and medical device portfolio. Prior to that, he spent seven years at PaineWebber Ventures/Ampersand Ventures in Boston, where as a Managing General Partner he concentrated on early stage technology and biotechnology investments for a series of partnerships affiliated with PaineWebber. Mr. Mills received an A.B. in Chemistry, cum laude, from Princeton University, an S.M. in Chemistry from the Massachusetts Institute of Technology (organometallic photochemistry) and an M.S. in Management from MIT's Sloan School of Management. |
 |
| Matthew
I. Hermann, Director,
Strategic Health Venture Investing Matt Hermann actively leads Ascension Health Ventures’ efforts to identify and fund innovative companies that can directly benefit Ascension Health’s ministries and offer the potential for strong investment returns. Before joining Ascension Health Ventures, he served for five years, most recently as vice president with Atlantic Medical Management, LLC, a New York-based venture capital management company focused on early- to mid-stage healthcare services and information technology companies. Prior to that, Mr. Hermann served in financial management roles at two publicly traded healthcare companies, Nutrition 21, Inc. and Regeneron Pharmaceuticals, Inc., and worked at J.P. Morgan Chase & Co. and PricewaterhouseCoopers in New York City. Mr. Hermann is a board observer at several portfolio companies. He holds a Bachelor’s of Science degree in engineering science from Tufts University, College of Engineering, and a master’s of business administration degree in finance from New York University, Leonard N. Stern Graduate School of Business. |
 |
| Dr.
Maggie Flanagan, Global
Alliance Director, Enabling Science, Technology and Information Dr. Maggie Flanagan is the Global Alliance Director for Enabling Science, Technology and Information at AstraZeneca Pharmaceuticals. Prior to joining AstraZeneca, Dr. Flanagan was the Senior Director, Business Development at Hybridon, Inc., Cambridge, MA, President, BioAlliance, Inc., Lexington, MA, Director, Licensing and Proprietary Drug Discovery, Oncogene Science Inc., Cambridge, MA, and Senior Scientist, (Marion) Merrell Dow Pharmaceuticals, Cincinnati, OH. She has a B.S. in Chemistry from the University of Kansas, and a Ph.D. in Physical Chemistry from Indiana University, Bloomington. |
 |
| Dr.
James Fickett, Director,
Strategic Capabilities, Discovery IS and Informatics Jim Fickett entered the field of bioinformatics in 1980 as one of the founders of GenBank. He was active in the development of sequence analysis algorithms for many years, pioneering in the development of algorithms for gene structure prediction and analysis of transcriptional regulatory regions. He joined SmithKline Beecham in 1996 and headed the Bioinformatics Research Group there. He now heads scientific and strategic aspects of IS and Informatics for AstraZeneca. |
 |
| Jean-François
Formela, Senior
Partner Jean-François Formela joined Atlas Venture in 1993. Previously, he was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough in the US. During his tenure there, he was responsible for the marketing of Intron A, Schering-Plough's alpha-interferon. In his last position at Schering-Plough, he directed the US Phase IV studies in all therapeutic areas, as well as the health economics, medical information, and biotechnology pre-marketing groups. As a medical doctor, Jean-François practiced emergency medicine at Necker University hospital in Paris. Since joining Atlas Venture, Jean-François
has been involved in the formation of companies such as ArQule (Nasdaq:
ARQL), MorphoSys (Neuer Markt: MORG), Exelixis (Nasdaq: EXEL), deCODE
genetics (Nasdaq: DCGN), Variagenics (Nasdaq: VGNX), Structural
GenomiX, CellZome, Archemix and Akceli. Board participation includes: |
 |
| Michael
King, Managing Director, Healthcare Group Michael King is a Managing Director and Senior Equity Research Analyst in the Health Care Group at Banc of America Securities LLC where he covers the biotechnology sector. Mike joined Banc of America Securities in 2002 from Robertson Stephens, where he had been a Managing Director and Senior Biotechnology Analyst since 1998. Prior to that, he served as senior biotechnology analyst at Vector Securities from 1996 to 1998 and at Dillon, Read & Co. from 1994 to 1996. He has also held positions at D. Blech & Company, Alex Brown and Sons, Hambrecht & Quist and Kidder, Peabody & Company. He earned a BBA with honors in finance from Baruch College. Mike was ranked fourth for his stock-picking accuracy in The Wall Street Journal’s annual “Best on the Street” survey in 2001 and was given the Institutional Investor Home-Run Hitter award in 2000 for his coverage of OSI Pharmaceuticals. |
 |
| Stephen
Ober, President Dr. Ober is the Senior Managing Executive with overall responsibility for the company. Dr. Ober comes to Beyond Genomics from Synergy Health Care, Inc., a company that he founded and where he served as President and CEO from 1995 to 2000. Dr. Ober was instrumental in establishing Synergy as a leading informatics company in the Health Care and Pharmaceutical Industries. Synergy is now a division of Quintiles Transnational, the largest provider of outsourced drug development, commercialization and health care informatics to the global pharmaceutical industry. In addition to over 15 years in the health care, informatics and life sciences, Dr. Ober received his MBA from Harvard Business School and his MD degree from Boston University School of Medicine. |
|
| Dr.
Gurinder Shahi MBBS, PhD, MPH, CEO
and Principal Consultant Dr. Shahi is a physician with training in molecular
biochemistry and in international health policy and management.
He is a leading expert on change management and strategic program
implementation in healthcare and the life sciences. He has played
a key role in the development of several major international initiatives
including the International Vaccine Institute (now based in Seoul,
Korea) and the Asia-Pacific International Molecular Biology Network,
and has served as advisor and consultant to leading international
organizations, governments, corporations and foundations. He has
also been actively involved in establishing and providing strategic
and management input to a range of start-up enterprises including
Lynk Biotechnologies, Asia Pacific Genomics, and DNA Phenomics,
and in helping a growing number of US, European and Australian enterprises
build their operations in Asia. [MBBS, PhD - National University of Singapore; MPH - Harvard University; Warren Weaver Fellow - The Rockefeller Foundation] BioEnterprise Asia; email: gurinder.shahi@bioenterprise.org
|
|
| Hoda
Abou-Jarma, Founder
& CEO During the course of her career, Ms. Abou-Jamra has established a solid network of contacts in U.S. Biotechnology and venture capital firms. Before founding BioExec Ventures, LLC, Ms. Abou-Jamra was in business development at Acumen Sciences, a newly-launched research firm for the biotechnology and pharma industries. Previous to Acumen, she held a business development position at Incyte Genomics. Before joining Incyte she was involved in the early stage of Pure Tech Ventures, which creates and develops companies based on innovative life science technologies that often represent the convergence of several areas of research and development. Ms. Abou-Jamra now serves as a business advisor for that group. Her past bio/pharma experience includes a successful sales, Marketing and Business Development position at Boiron Laboratories and Bayer Corporation. Prior to that she lead NPC Inc., a private consulting firm specializing in business, marketing, and fundraising for customers such as Alliance Imaging Inc., and ATI systems. In addition to her career pursuits, Ms. Abou-Jamra has also served on several finance and fundraising committees, including Senator John Kerry's campaign finance committee and service as a board member for the Massachusetts Women's Political Caucus, where she chaired the Abigail Adams fundraising event for two years. She is also a member of the Academy of Managed Care Pharmacists, American Pharmaceutical Association, the Boston Association of Retail Druggists and Fenway Community Health Center. Ms. Abou-Jamra graduated from the Bouve College of Health Sciences, Northeastern University with a degree in Pharmacy. She is fluent in French, English, and Arabic.. |
| Dr.
Vibha Ahuja, Deputy General Manager Dr. Vibha Ahuja did her M.Sc. and PhD. In Microbiology
from Department of Microbiology, Panjab University, Chandigarh,
India. She had been working in BCIL for last 10 years and has undertaken
several assignments in the area of technology transfer, consultancy
ranging from conducting techno market surveys, preparation of project
feasibility reports, to preparation of business plans and status
studies and organizing workshops on current topics of interest in
biotechnology like biosafety regulations, biodiversity conservation
etc. She is also associated with the preparation of the National
Biodiversity Strategy and Action Plan (NBSAP) project of UNDP/GEF
being coordinated by BCIL on behalf of Ministry of Environment and
Forests, Government of India. |
|
| Dr.
Robert Mashal, Partner Rob focuses on investment opportunities in life sciences. Rob was previously a Program Executive with Vertex Pharmaceuticals, where he led cancer drug development strategy and oversaw pre-clinical/clinical development, marketing, regulatory, and business activities. He was also a member of the Joint Research Committee for the $800 million Vertex-Novartis collaboration. Prior to that, Rob was an Associate with McKinsey & Company where he served clients in the pharmaceutical, medical device, insurance, and healthcare payer-provider industries. He was previously a Researcher and Attending Physician at Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Harvard Medical School. Rob is a diplomate in both internal medicine and oncology. Rob is a Director or Board participant of EpiGenesis Pharmaceuticals, Novalar Pharmaceuticals and GlycoFi. Rob is a Phi Beta Kappa graduate of Johns Hopkins University and received his M.D. from Johns Hopkins University School of Medicine. |
|
| G.
Steven Burrill, CEO G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for 35 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. Mr. Burrill currently serves as Board Chairman for Paradigm Genetics (NASDAQ: PDGM) and Pyxis Genomics and as a Board member of Catalyst Biosciences, DepoMed (AMEX: DMI), Galapagos Genomics, Inhibitex (observer), Targacept, and Third Wave Technologies (NASDAQ: TWTI). Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50). Mr. Burrill is a founder of the Foundation for the National Medals of Science and Technology. He also serves on the Boards of the Bay Area Bioscience Center, the Bay Area Science Infrastructure Consortium, the California Healthcare Institute, the Exploratorium, and the Kellogg Center for Biotechnology. Mr. Burrill is also on the Advisory Boards of the University of California, San Francisco (UCSF) Foundation, the University of Hawaii Medical School, and the University of Wisconsin Foundation. In addition, he is a member of The World Bank’s “Out of the Box” group as well as an adjunct professor at UCSF. |
|
| Pierre
Cantin, Partner,
Biotechnology & Life Sciences Pierre Cantin joined CDP Capital – Technology Ventures in 2001 and currently holds the position of Senior Partner. Mr. Cantin has nearly 20 years of experience, with 10 years in the life sciences sector, specifically mergers and acquisitions. Before joining CDP Capital – Technology Ventures, he held the position of Senior Vice-President and Director of KPMG Corporate Finance, where he took part in several mergers and acquisitions, company sales, private placements, strategic alliances and business valuations. More specifically, he acted as the principal financial advisor in several acquisitions, including Technilab Pharma (acquired by Merckle GmbH) and Draxis Health (TSE: DAX), as well as in a number of divestitures. Prior to that, he occupied various commercial and management positions with the Royal Bank of Canada, including three years as head of the Montreal Life Sciences Group during which time he put in place new financing for several companies in this sector. Mr. Cantin holds a Master of Business Administration, with a major in Finance, from the École des Hautes Études Commerciales and a Bachelor of Education, with a major in Exercise Physiology, from McGill University. He is also a graduate of the Canadian Securities Institute. Board Participation: Angiogène, Chronogen, Eximias Pharmaceuticals |
 |
| Dr.
Nathan Zhang, President Prior to joining Chipscreen, Dr. Zhang was the Managing Director at Delirium, a global strategic consulting company in New York. Dr. Zhang was a senior consultant at KPMG LLP's New York office before Delirium. Prior to joining KPMG, Dr. Zhang also worked for investment bank Credit Suisse First Boston's investment banking group in New York. Dr. Zhang was a co-founder of CDR Therapeutics, Inc., a Seattle-based bio-pharmaceutical startup that develops products for the treatment of AIDS, psoriasis, corneal healing after laser keratotomy, and breast cancer. Dr. Zhang is the inventor of several U.S. patents and author of three nature biotechnology papers. Dr. Zhang was awarded James A. McLaughlin Award from American National Student Research Forum for his research in the Field of Immunology and Infectious Disease. Dr. Zhang was also awarded Brupbacher Young Investigator Award for his novel approaches to cancer therapy from Charles Rudolph Brupbacher Foundation in Switzerland. Dr. Zhang received his M.D. from Tianjin Medical University. Dr. Zhang also holds a Ph.D. in pharmacology from the University of Pennsylvania and an MBA from the University of Chicago with a concentration in Finance and Accounting. |
 |
| Roger
D. Feldman, Principal Roger Feldman is a principal in the Corporate and
Securities Group of the national law firm of Fish & Richardson
P.C. Mr. Feldman has served as corporate counselor and advisor to
a broad range of clients from entrepreneurs, to maturing companies,
to major corporations. His practice is concentrated in corporate
finance, mergers and acquisitions, public and private securities
offerings, and general corporate transactions. Mr. Feldman has handled
all phases of business and corporate planning, structuring, and
organization; various phases of corporate finance (early and later
stage, including debt and equity); contract negotiations, strategic
alliances, and contractual and other commercial dealings; and stockholder
disputes. His practice is international in scope: he has been involved
in deal making throughout the world. |
 |
| P.
Louis Myers, Ph.D.,
Principal Louis Myers, Ph.D., is a principal of the national law firm of Fish & Richardson P.C. Dr. Myers counsels life sciences clients on the formation and execution of intellectual property strategies, usually in the context of over all business planning and management including product development, technological issues, competitive and collaborative relationships, financing strategies, and the acquisition of technology, and other business considerations. This can include patent drafting and prosecution; the provision of infringement, validity, freedom-to-operate, and patent landscape opinions; due diligence investigations; and drafting and analyzing IP-related licenses and other agreements. Dr. Myers has worked in most of the technologies and fields important to life sciences companies, including basic molecular biology, geno /prote /pheno /chemo /glycomics, bioinformatics, chip-array technologies, small molecule/organic chemistry, drug discovery, gene and cell-based therapies, immunology, antibody-based therapies and diagnosis, transgenic animals and plants, DNA sequence analysis, nucleic acid detection and amplification systems, the use of lasers in medicine and surgery, and medical and biochemical instrumentation and devices. Dr. Myers earned his Ph.D. in Biology from Harvard University, where he also did his Postdoctoral work. He earned his law degree from Harvard Law School. He has taught Patent Law at Suffolk University Law School. |
 |
| Noubar
B. Afeyan, Ph.D., Senior
Managing Director & CEO Noubar B. Afeyan, Ph.D., Senior Managing Director
and CEO of Flagship Ventures, is a recognized technologist and entrepreneur.
With $600M under management, Flagship Ventures is a leader in creating,
funding and developing new ventures in both life science and information
technology sectors. Dr. Afeyan is also a Senior Lecturer at MIT's
Sloan School of Management and is a frequent guest speaker at technology
forums throughout the country. He has authored numerous scientific
publications and patents. He holds a Ph.D. in Biochemical Engineering
from the Massachusetts Institute of Technology. Dr. Afeyan currently serves as a Director for Flagship portfolio companies Adaptive Therapeutics, Affinnova, Beyond Genomics, Compound Therapeutics, engeneOS, Genstruct, and Helicos. In addition, he serves on advisory boards for Boston University Medical School, the Whitehead Institute at MIT, the McGowan Institute at the University of Pittsburgh, the Center for Bits and Atoms at MIT’s Media Lab, and the Faculty of Engineering at McGill University. He is also a Board member of several economic development organizations aimed at rebuilding the former Soviet Republic of Armenia. |
 |
| R.
Nelson Campbell, Senior Vice President, Life Sciences Investment Banking Friedman, Billings, Ramsey Group, Inc. R. Nelson
Campbell is Senior Vice President and Head of Life Sciences Investment
Banking at Friedman, Billings, Ramsey & Co., Inc. From 1991 to 1996, Mr. Campbell was the co-founder, Vice President of Business Development and Treasurer of OsteoArthritis Sciences, Inc., a venture capital-financed drug discovery company. From 1986 to 1991, Mr. Campbell was engaged in corporate finance and merger and acquisition transactions while working for the international investment banking firms of Merrill Lynch Capital Markets, Nomura Securities International, and Daiwa America Securities, Inc. |
 |
| Jan
van Heek, Executive
Vice President, Therapeutics & Genetics Jan van Heek joined Genzyme in 1991. |
 |
| Dr.
Hans A. Küpper, Partner Dr Hans Küpper has over 30 years of experience in the field of biotechnology in areas from research up to R&D management, technology assessment and business acquisitions. He received his PhD at the University of Heidelberg in 1974. After additional academic research at the Massachusetts Institute of Technology and Heidelberg University he joined Biogen, Geneva, where he held various R&D positions, the last as Assistant Research Director. In 1985, he joined Behringwerke AG, Marburg, to head its Molecular Biology Department. Since 1991, he was increasingly involved in deal negotiations and various aspects of company restructuring such as acquisitions, spin-offs and joint ventures. In 1999, he joined Global Life Science Ventures, Munich and is board member of several portfolio companies. Dr Küpper is author of numerous publications and served as consultant to the Pharmaceutical Industry and the European Commission. |
 |
| Mark
R. Saunders, President As President of GMCG, LLC, Mark is a leading investment banker to international public and private life science companies. He has a successful history of cross border mergers and acquisitions and cross border joint ventures. Mark has significant expertise in the US listing process and in all forms of financing available to domestic and international companies. He leverages his extensive contacts both on Wall Street and in the international financial markets to arrange and maximize financial opportunities for our clients with market makers, international traders, institutional public and private funds and high net worth investors. Mark holds a JD from New York Law School and is a member of the New York Bar Association. |
 |
| Gregory
V. Stento, Managing Director Mr. Stento joined the Firm in 1998. He was previously a Managing Director at Comdisco Ventures, where he provided equity and debt capital to startup and emerging growth technology and life sciences companies. Prior to joining Comdisco, Mr. Stento was a General Partner at Horsley Bridge Partners where he was responsible for making and managing investments in a variety of private equity partnerships and companies. Mr. Stento also spent six years in marketing and sales at NCR Corporation, where he focused on information technology solutions for financial institutions. Mr. Stento received a bachelor's degree, with distinction, from Cornell University and an MBA from Harvard Business School. He serves on several advisory boards including Canaan Partners, Healthcare Ventures, Heritage Partners, Polaris Venture Partners, Redpoint Ventures and Versant Ventures. |
 |
| Richard
E. Kuntz, M.D., M.Sc,
Chief Scientific Officer Richard E. Kuntz is the Founder and Chief Scientific
Officer of the Harvard Clinical Research Institute (HCRI), a leading
CRO located within the unique world-class patient care and research
environment of the Harvard Medical School and affiliated institutions.
He is Associate Professor of Medicine at Harvard Medical School,
the Chief of the Division of Clinical Biometrics at the Brigham
and Women’s Hospital and an interventional cardiologist in
the Division of Cardiovascular Diseases at the Brigham and Women’s
Hospital. |
 |
| O.
Prem Das, Ph.D.,
Director, Office of Technology
Licensing & Industry Sponsored Research Prior to joining OTL, Prem was Associate Director of the Office of Industrial Affairs at Memorial Sloan Kettering Cancer Center, and was Director of Business Development for Cadus Pharmaceuticals of Tarrytown, NY from 1996 until 1999. He worked with a start-up biotechnology company for several years prior to joining Cadus, first as Director of Research and subsequently as President and acting CEO. He has also worked as a business development consultant in the biochip area. Prem received his Ph.D. in 1980 from the Chemistry Department at MIT and has academic research expertise in several areas of modern biology. |
| Dr.
John Burt, Head
of Medical Sciences Team John leads the Imperial Innovations team with responsibility for projects arising from the Faculties of Medicine and Life Sciences. Imperial College’s medical school is one of Europe’s largest and has close links with five major NHS hospital trusts in the West London area. Prior to joining Imperial Innovations, John worked in a variety of strategy, business and corporate development roles for GlaxoSmithKline, including responsibility for the divestiture of Affymax by GSK. His early career began as a management consultant with PricewaterhouseCoopers, before moving to Vernalis and taking responsibility for R&D finance. John sits on the board of directors of Sterix and Harefield Cardiac and has close links with other Imperial College spin-outs including Synovis and Protexeon. John has a first degree in Natural Sciences (Biochemistry) from University of Cambridge, supplemented with a D.Phil from University of Oxford in Molecular Biology. He is a member of the Chartered Institute of Management Accountants. |
 |
| Steven
Holtzman, CEO
Steven H. Holtzman is a founder and the President and Chief Executive Officer of Infinity Pharmaceuticals, Inc. He previously was the Chief Business Officer of Millennium Pharmaceuticals, Inc. (NASDAQ: MLNM), the founder and Executive Vice President of DNX Corporation, the founding Executive Director of the Ohio Edison Program, and an instructor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K. Mr. Holtzman co-founded and from 1995-2000 was the Co-Chair of the Biotechnology Industry Organization (BIO) Bioethics Committee. From 1996-2001 he was a member of the National Bioethics Advisory Commission; he has served as a member of several NIH and NAS advisory committees pertaining to the ethics of life science research; and, he is a Trustee of The Hastings Center for Bioethics. Mr. Holtzman received his B.A. in Philosophy from Michigan State University and his B.Phil. graduate degree in Philosophy from Oxford University, which he attended as a Rhodes Scholar. |
 |
|
Jean-Pierre
Saintouil,
Director of the Technology Transfer Office Graduate in Biochemistry, Genetics and Post Graduate in Strategic Business Management of the European School of Management (ESCP-EAP) Paris – France. His experience comprises 19 years of International sales, Marketing and Business Development. Former Strategic Marketing Director for Sanofi Diagnostics Pasteur, Beckman and Bio-Rad he is, since September 2000, the Director of the Office of Technology Transfer at Institut Pasteur in charge for the licensing of Diagnostics, Vaccines and Therapeutics patents. |
 |
| Mario
Gobbo, Head of Life Sciences Mario Gobbo is in charge of Life Sciences investments for IFC. He previously worked with Lazard Brothers in London where he managed their Central and Eastern European practice. He began his career as a commercial and later an investment banker in Milan and London with several financial institutions. He has over 20 years of banking experience, which spans pharmaceuticals and biotechnology, as well as oil and gas, telecommunications, power and financial institutions. He worked on the initial public offering of Ares Serono, now Serono, the largest European biotech company, and of Pliva from Croatia, the most prominent pharma company in Central Europe. He also was on the board of a small US biotech start-up and personally invested in several biotech companies. He holds a BA from Harvard College, an MSc from the University of Colorado and an MBA and a PhD in finance from the Wharton School of the University of Pennsylvania. |
 |
| Stan
Yakatan, Chairman After 30 years as a successful CEO, entrepreneur,and operational manager, Stan Yakatan has dedicated the last 7 years of his career to sharing his experiences with management teams interested in building technology based companies. His experience as an executive and in several instances serving as CEO with New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific and Biosearch, provided him with management and corporate finance acumen that he enjoys sharing with others. He has founded or co-founded in excess of 15 companies in the United States, Canada, Israel, France and Germany and in many cases served as the initial CEO, and Chairman of these companies. He currently sits on the board of directors of several public and private companies and has advised several of the world's leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA) and Biocapital (Canada). He has completed and advised on numerous acquisitions and corporate finance transactions raising in excess of $1.0 billion dollars in the public and private capital financing markets. He is a frequent speaker at financial and biotechnology conferences throughout the world speaking on topics including, "Capital Raising for the Technology-Based Start-Up" and "The Need to be Global in the Quest for Capital and Partners". Rick Biondi, Editor of Lab Business Magazine stated," Mr Yakatan is a venture capital raising Guru and it is part of his genetic make up." He currently serves as the strategic advisor to the state government of Victoria, Australia and is the Chairman of Katan Associates International with headquarters in New York City. |
 |
| Eileen
Smith Ewing, Esq, Partner
& Chair, Life Sciences Group Eileen Smith Ewing represents biotechnology and
high-technology clients in intellectual property licensing and technology
transfers. In addition to a complex transactional practice, she
provides ongoing counsel to corporations, partnerships, and limited
liability companies on a wide range of legal matters. Ms. Ewing
also provides her private and public companies in domestic and transnational
mergers, acquisitions, joint ventures, and other strategic corporate
alliances. She has experience in counseling issuers, underwriters,
and venture capital funds with respect to public offerings and private
placements of securities. |
 |
|
Lita Nelson, Director,
Technology Licensing Office Lita Nelsen is the Director of the Technology Licensing Office at the Massachusetts Institute of Technology, where she has been since 1986. This office manages over 400 new inventions per year from M.I.T., the Whitehead Institute, and Lincoln Laboratory. Typically, they negotiate over 100 licenses, and start up over 20 new companies per year. Ms. Nelsen earned B.S. and M.S. degrees in Chemical Engineering from M.I.T. and an M.S. in Management from M.I.T. as a Sloan Fellow. Prior to joining the M.I.T. Technology Licensing Office, Ms. Nelsen spent 20 years in industry, primarily in the fields of membrane separations, medical devices, and biotechnology, at such companies as Amicon, Millipore, Arthur D. Little, Inc., and Applied Biotechnology. Ms. Nelsen was the 1992 President of the Association of University Technology Managers and serves on the board the Mount Auburn Hospital, and the Scientific Advisory Board of the Children’s Hospital Oakland Research Foundation. She serves as the intellectual property advisor to the International AIDS Vaccine Initiative and is a founding and current board member of the Center for Management of Intellectual Property in Health Research. Ms. Nelsen is widely published in the field of technology transfer and university/industry collaborations and was a CMI Fellow at the University of Cambridge with the Cambridge MIT Institute studying university /industry/ government partnerships in technology transfer and local economic development. She is a co-founder of Praxis, the UK University Technology Transfer Training Programme. Contact info: Email: lita@mit.edu |
 |
| Dr.
Edward M. Scolnick, President
Emeritus Dr. Scolnick is President Emeritus, Merck Research Laboratories. From 1982 to 2003, Dr. Scolnick served in multiple capacities as President, Merck Research Laboratories and Executive Vice President for Science and Technology, Merck & Company, Inc; Executive Director and Vice President, Department of Virus and Cell Biology, and Senior Vice President, Basic Research, Merck Research Laboratories. Prior to joining Merck, Dr. Scolnick worked at the National Cancer Institute where his work demonstrated the cellular origin of sarcoma virus oncogenes in mammals and defined specific genes that cause human cancer. He also worked at the National Heart Institute where his work defined the stop signals in the genetic code and the biochemical mechanism that produces the stops. Dr. Scolnick was elected to the National Academy of Sciences in 1984 and to the American Academy of Arts and Sciences in 1993. He became a member of the Institute of Medicine in 1996 and served on the Board of Directors of Merck & Co., Inc. from 1997 - 2002. He recently was selected as Regents’ Lecturer, University of California Berkeley, Frank H.T. Rhodes Class of ’56 University Professor at Cornell University, and appointed to the Board of Visitors at the University of Pittsburgh School of Medicine. He currently serves on the Board of Directors for Millipore Corporation, Renovis, Inc., Harvard Medical School, Protein Pathways, TransForm Pharmaceuticals, Inc., Medical and Scientific Advisory Board for MPM Capital, Hypnion, and Protemix. He was also a Member of the FDA Science Board from 2000 - 2002. Dr. Scolnick’s commitment to the mental health field is evidenced by memberships on the Board of Directors for McLean Hospital, McGovern Institute for Brain Research, and is President of the Pennsylvania Montgomery County Chapter of the National Alliance for the Mentally Ill. He is also a board member of the National Institute of Mental Health Council. Dr. Scolnick holds an A.B. from Harvard College and a M.D. from Harvard University Medical School.. |
 |
| Robert
Mulroy, President
& CEO Robert Mulroy is a President & CEO of Merrimack Pharmaceuticals, Inc. Founded by leading scientists from MIT and Harvard, Merrimack is focused on the discovery and development of novel therapeutics for cancer and autoimmune diseases. The Company's competitive advantage is its Network BiologyTM discovery platorm: an integrated technology, biology, and computing capability to profile the complex protein-protein interactions that govern cellular pathways. The Company's lead product is currently in a patient study of rheumatoid arthritis with three others in various stages of research and development. Mr. Mulroy previously served as CEO of Atlantic BioPharmaceuticals and as a strategy consultant. He completed his undergraduate degree at Stanford and graduate work at Yale. |
| Ian
Nisbet, Ph.D.,
Senior Director, Oncology Alliance
Management and EU Strategic Marketing Ian Nisbet, Ph.D. works at Millennium Pharmaceuticals, Inc. (MPI) where he is currently Senior Director, Oncology Alliance Management and EU Strategic Marketing. In this role Ian is responsible for managing the global VELCADE strategic alliance between Millennium and the J&J family of companies, with particular emphasis on the EU interface. Prior to this role, Ian was Product Leader for VELCADE, where he led the team that was responsible for obtaining FDA approval and launching this novel oncology drug in May 2003. Ian originally joined Millennium through its then subsidiary, Millennium BioTherapeutics (MBio), as Program Director for the Therapeutic Antibody Program in February 1998. When MBio was merged into MPI in December 1999, Ian moved into the position of Senior Director, Licensing and M&A in Millennium’s Corporate Development group. In this role, Ian supported Millennium’s extremely aggressive growth objectives through the development and implementation of strategic M&A and licensing initiatives. During 2001, Ian was a key member of the team that successfully negotiated Millennium’s first two in-licensed clinical products (both oncology drugs). In the same year, Ian led the diligence team for Millennium’s acquisition of COR Therapeutics and then went on to lead the merger integration team and become the site manager for Millennium San Francisco (the ex-COR site). Upon returning to Boston in mid-2002, Ian moved on to the VELCADE project. Before joining Millennium, Ian worked for the Australian pharmaceutical company CSL Limited in a career spanning more than 17 years. At CSL Ian held a number of different scientific and management positions, the last being Director, Planning and Coordination. In that position Ian was responsible for the development and implementation of project management at CSL, together with overall management of CSL’s project management system and direct management of a number of CSL’s external relationships. Ian received his B.Sc. in microbiology and biochemistry from the University of Melbourne and his Ph.D. in molecular biology from Monash University. He is also a graduate of the Advanced Management Program from the Melbourne Business School at the University of Melbourne. |
 |
|
Robert
E. Mast, Managing
Director Mr. Mast is a Managing Director of Monument Group, a specialized placement agent dedicated to representing superior private equity and alternative investment opportunities. Prior to joining Monument Group in February 1996, was a Consultant at Cambridge Associates, Inc., where he specialized in working with a variety of the firm's institutional and family group clients on alternative asset investing. Prior to joining Cambridge Associates, Mr. Mast had been Vice President at Venture Economics Information Services, a division of Securities Data Company, Inc. where he worked internationally with institutions and governmental entities designing and helping implement private equity investment programs. His former work experience includes a variety of management positions at Standard Oil Company, Oceaneering International Inc., and Schlumberger Ltd. Mr. Mast has a B.S. in Chemical Engineering from Princeton University and a M.B.A. from Harvard Business School. |
 |
|
Dr.
Ansbert Gadicke, Founding
General Partner Dr. Ansbert Gadicke is the Founding General Partner of the MPM Group. He led MPM's effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996. Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt. He subsequently held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT, Harvard University and the German Cancer Research Center. He has published in leading scientific publications including Nature and Cell. Dr. Gadicke is Chairman of Elixir and a Director of Arriva, Endeavor Pharmaceuticals, Kourion, Idenix Pharmaceuticals, Omrix Biopharmaceuticals, Pharmasset, and ViaCell. He previously served as a Director of BioMarin, Coelacanth, MediGene and Transform. He is a member of Advisory Councils for Harvard Medical School, the Health Science and Technology Program of Harvard and MIT, as well as the Whitehead Institute at MIT. He serves as the Co-Chairman of the Alumni Association of the Whitehead Institute and serves on the Board of the National Venture Capital Association (NVCA). |
 |
|
Theodore J. Roumel,
Assistant Director, Office of Transfer
Technology Primary responsibilities include strategic planning, intramural and extramural technology transfer policy, legislative, international and governmental affairs. Also has oversight responsibility for license monitoring and royalties administration activities. Serves as the Executive Secretary for the Public Health Service Technology Transfer Policy Board. Holds advanced degrees in Counseling Psychology and Public Health, awarded the designation as a Certified Research Administrator, and has authored a number of articles in professional and refereed journals.. |
|
Otello Stampacchia,
Head of life Sciences Investments Otello joined NIB Capital in 2001 from Lombard Odier, where he managed the Immunology Fund, one of the world's largest funds investing in US and EU public and private Biotechnology companies. Previously, he was at Goldman Sachs in London in their HealthCare corporate finance and M&A group. Prior to that, he started the Life Sciences activity of Index Securities (now Index Ventures), in Geneva. Graduated from Geneva University with a PhD degree in Molecular Biology, and with an European PhD in Biotechnology, Otello brings to portfolio companies a strong scientific background but also the understanding of public and private healthcare markets, specialized knowledge of Biotech Intellectual Property, and transaction experience. |
 |
|
Dr. Sam Fazeli,
Senior Biotechnology Analyst Sam’s coverage is mainly focused on UK small and mid-cap biotechnology companies. In the near future coverage will be expanded into continental Europe while maintaining a focus on biotechnology. Sam has been covering the UK and European sectors for the past 7 years. His background as a pharmacologist with extensive post-doctoral experience of molecular biology and genetic sciences has positioned him well to judge the scientific merit and commercial potential of new technologies and products. |
 |
|
Dr. Jeremy Levin,
Global Head of Strategic Alliances Jeremy is the Global Head of Strategic Alliances for Novartis Institutes. In this position Jeremy is responsible both for evaluating and managing current alliances with academia and biotechnology, interfacing with the venture community and establishing strategic collaborations to further the research mission of NIBR. From 1996 to 2000, Jeremy served as the Chairman of Physiome Sciences, Inc., and was appointed as Physiome's President and Chief Executive Officer in 2000. From 1998 through 1999 he was Managing Director of Perseus Capital LLC and from 1992 to 1998, Jeremy served as the President and Chief Executive Officer of Cadus Pharmaceutical Corporation, where he also served as Chairman from 1996 to 1998. Prior to 1992, Jeremy was a Vice President at IG Laboratories, a wholly owned subsidiary of Genzyme Corporation. In these positions, Jeremy developed and lead multiple collaborations with partners from academia, biotech through to major pharmaceutical companies. Jeremy has served on the Executive Committees and Boards of several public biosciences companies, including the executive committee of BIO and the Boards of the Biotechnology Institute and the New York Biotechnology Association. Jeremy received an MB.BChir. from the University of Cambridge and a D.Phil. in DNA structure from the University of Oxford. |
 |
|
Michael
Lytton,
General Partner Michael Lytton joined Oxford Bioscience Partners in 2000. Prior to that, he was Partner, Chairman of the Technology Group and a member of the Executive Committee of Palmer & Dodge LLP, a Boston-based law firm. Mr. Lytton serves on the Boards of Directors of Acambis, Alantos, Descartes Therapeutics, GPC Biotech, Graffinity Pharmaceuticals, Rib-X Pharmaceuticals, and VaxInnate Pharmaceuticals. Mr. Lytton was also responsible for investments by Oxford in Concentric Medical, Genpath Pharmaceuticals, and NuVios Pharmaceuticals. Mr. Lytton is also a member of the Research and Technology Development Committees of the Beth Israel Deaconess Medical Center (an affiliated Harvard teaching hospital) and the Center for Blood Research, Harvard Medical School, where he is also a member of the Board of Overseers. In addition, he serves on the Advisory Committee to Connecticut Innovations, a public agency funding early-stage biomedical companies in Connecticut. Mr. Lytton writes a column on issues facing early-stage biomedical companies for Start-Up magazine, published by Windhover Information. Mr. Lytton has served on the Executive Board of the MIT Enterprise Forum and the Patent Committee of the Boston University Medical Center. Mr. Lytton was a summa cum laude graduate of Princeton University and a recipient of a Fulbright Scholarship for study at the University of London. Mr. Lytton received a J.D. degree cum laude from Harvard Law School. Mr. Lytton also received a M.Sc. degree in Epidemiology and Medical Statistics from the London School of Hygiene and Tropical Medicine. |
 |
|
Dr. Ravi Kiron,
Dr. Kiron has been at Pfizer since 1991 contributing to drug discovery in the Cardiovascular & Metabolic Diseases Department. He obtained experience in drug development in the Project Management Department shepherding the progress of a discovery stage compound through early phases of clinical development. Dr. Kiron earlier earned a B.Sc. in Chemistry and a M.Sc. in Microbiology from Bombay University and a Ph.D. in Biochemistry from the Indian Institute of Science in Bangalore, India. Dr. Kiron then came to the Cardiovascular Center of Cornell University Medical Center-The New York Hospital, New York, NY where he stayed on to hold joint appointments as a tenure track Assistant Professor of Biochemistry and Medicine. He came to Pfizer from Cornell and earned his MBA degree from Rensselaer (RPI) at Hartford, CT. Dr. Kiron is an experienced pharmaceutical industry scientist and strategic analyst with significant experience in management, leadership and problem solving. He has diverse experience and a broad perspective of the various processes of pharmaceutical drug discovery, pre-clinical and early clinical drug development, project management, external technology investments and licensing. Dr. Kiron also managed until recently the discovery protein outsourcing activities as well as the licensing of research tools for research in genetic therapies and genomics. His current responsibilities include business and competitive analysis of the biotechnology and pharmaceutical industry, providing insight into their strategies and benchmarking their activities. Dr. Kiron also participates in the analysis of new technology opportunities, potential pharmaceutical and biotechnology Mergers & Acquisition opportunities for Pfizer and is involved in strategic planning for future collaborations. |
|
Dr.
Christoph Westphal, General
Partner Christoph H. Westphal is a general partner in our Boston office. Christoph joined Polaris in June 2000. He focuses on investment opportunities in medical technology and material science. Experience: Prior to joining Polaris, Christoph was at McKinsey & Co. in Boston and Los Angeles, working with high-growth biotech, pharmaceutical, materials science, wireless, and e-commerce companies. He was lead author on several papers published in Cell and Nature Genetics and is the inventor on two patents in the areas of cancer genetics and metabolic diseases. Boards: Christoph represents or has represented Polaris on the boards of directors of Advion BioSciences, Athenix Corp, Saegis Pharmaceuticals, eNOS Pharmaceuticals, Hydra BioSciences, and Nanosys. He was also founder and start-up CEO, and serves as vice chairman of both Momenta Pharmaceuticals, Inc. and Alnylam Pharmaceuticals. Education: Christoph completed his MD at Harvard Medical School and his PhD in genetics at Harvard University in six years. He majored in economics, literature, and biology while completing a BA summa cum laude and Phi Beta Kappa at Columbia University in three years. After graduating from Columbia, and prior to graduate schools, Christoph spent one year working with a medical team and studying in Cameroon and at the Albert Schweitzer Hospital in Africa, and worked for one year at a Max Planck Institute in Germany as a Fulbright/DAAD scholar. |
 |
|
James
M. Garvey, CEO
& Managing Partner James joined SVLS in May 1995 as Chief Executive
Officer and Managing General Partner of SVLS, overseeing its approximately
$900m investment activity. James brings a successful healthcare
investment track record, preceded by 18 years of operating management
experience. Prior to joining SVLS, he was Managing Director for
the $600m Venture Capital Division of Allstate Corporation preceded
by managing Allstate’s health care investment activity. He
has held several senior management positions in companies with multinational
operations including Kendall (TyCo) & Millipore. He was also
president of start-ups Allegheny International Medical Technology
and National Teledata. James has served on the boards of private
and public companies in the US and Europe including public companies
Alscript Pharmaceuticals, Arris Pharmaceuticals, LaserVision Centers,
Orthovita, Shire Pharmaceuticals and SunRise Assisted Living. |
 |
|
Dr. Stelios Papadopoulos,
Ph.D., Vice
Chairman Dr. Stelios Papadopoulos is a Vice Chairman of SG
Cowen and as an investment banker he focuses on the biotechnology
and pharmaceutical sectors. Prior to joining SG Cowen in February
2000, he spent 13 years as an investment banker at PaineWebber,
Incorporated where he was most recently Chairman of PaineWebber
Development Corp., a PaineWebber subsidiary focusing on biotechnology.
He joined PaineWebber in April 1987 from Drexel Burnham Lambert
where he was a vice president in the Equity Research Department
covering the biotechnology industry. Prior to Drexel, he was a biotechnology
analyst at Donaldson, Lufkin & Jenrette. Dr. Stelios Papadopoulos is a co-founder and Chairman of the Board of Exelixis, Inc., and he is a co-founder and member of the Board of CellZome, Inc. and Anadys Pharmaceuticals, Inc. He is also a member of the Board of Directors of GenVec, Inc. and Structural GenomiX, Inc. In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé. |
 |
|
Antoine
Papiernik, General
Partner Antoine Papiernik is managing partner at Sofinnova Partners and invests in life sciences. He joined Sofinnova Partners in 1997. Antoine has an MBA from the Wharton School (University of Pennsylvania). He began his career in London as product manager at Unilever ’s Health & Beauty division. He then spent four years in Prague, first as a consultant, then as an investor for CDC-Participations (Caisse des Dépôts Group). He then moved to the newly formed venture capital firm CDC-Innovation, where he invested exclusively in life sciences. Antoine was an initial investor and board member of Actelion, a Swiss biopharmaceuticals company that is now listed on the Zürich stock exchange. He has also invested in and is a board member of NovusPharma, Diatos, SpineVision, EndoArt, Biolipox, Promed and Addex. |
 |
|
N.
Peter Kostopulos, Leader BioAlliance
Practice & Partner Life Sciences N. Peter Kostopulos is a partner in the Life Sciences Group of the law firm of Womble Carlyle Sandridge & Rice, and the leader of its BioAlliance Practice, a multi-disciplinary, industry-oriented group, which provides bio-pharma clients with legal and related business transaction support for their corporate partnering activities. For 15 years, Peter has represented private and venture-backed development companies on a variety of R&D and commercial alliances involving drug, diagnostic and medical device products. He has been particularly active in transatlantic transactions, providing European and American clients with assistance in negotiating and closing transactions with large pharmaceutical and biotech companies in the United States and Europe. Peter has participated in over 75 domestic and international collaborations and intellectual property transactions, many of which involved providing direct support to senior business development management, steering committees and alliance managers. His substantial litigation and previous government experience (FTC & Justice Department) provides clients with valuable assistance in avoiding and resolving costly litigation and government investigations. He is Chairman of the Strategic Alliances Committee of the Licensing Executives Society (USA/Canada), and has spoken at numerous U.S. and European conferences and written on a variety of topics relating to alliances, including early stage deal structuring, negotiating with big pharma, organizing and managing the alliance, conducting alliance due diligence, extracting value from and terminating R&D alliances, and the antitrust guidelines for intellectual property. He is a 1974 graduate of Georgetown University and 1978 graduate of the Georgetown University Law Center, and is a member of the bars of Washington D.C., Florida, Maryland and Virginia. He speaks French, and has lived outside the United States. |
 |
